Health and Fitness Health and Fitness
Thu, March 17, 2011
Wed, March 16, 2011
Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ] - Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011

Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16


//health-fitness.news-articles.net/content/2011/ .. nual-oc-growth-stock-conference-on-march-16.html
Published in Health and Fitness on Tuesday, March 8th 2011 at 10:50 GMT by Market Wire   Print publication without navigation


PASADENA, Calif.--([ BUSINESS WIRE ])--Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the Roth 23rd Annual OC Growth Stock Conference at 11:30 a.m. Pacific time on Wednesday, March 16, 2011. The conference is being held at the Ritz Carlton in Laguna Niguel, California.

Investors attending the conference are encouraged to schedule a one-on-one meeting at the conference with Arrowheada™s CEO Dr. Christopher Anzalone by contacting [ conference@roth.com ], or Brandi Floberg at [ arrowres@tpg-ir.com ] or 212-481-2050.

The presentation will be webcast live and can be accessed by visiting the Company's website at [ www.arrowheadresearch.com ]. A replay of the presentation will be archived on the Arrowhead website for 90 days.

About Arrowhead Research Corporation

Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company. For more information please visit [ http://www.arrowheadresearch.com ].


Publication Contributing Sources